Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

GERON CORPORATION (GERN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/04/2017 12/05/2017 12/06/2017 12/07/2017 12/08/2017 Date
1.89(c) 1.89(c) 1.94(c) 1.99(c) 2.03(c) Last
829 438 1 120 589 1 685 289 3 759 654 3 020 877 Volume
-2.07% 0.00% +2.65% +2.58% +2.01% Change
More quotes
Financials ($)
Sales 2017 1,15 M
EBIT 2017 -28,9 M
Net income 2017 -27,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 30,8 M
EBIT 2018 -5,32 M
Net income 2018 -4,64 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 282x
Capi. / Sales2018 10,5x
Capitalization 323 M
More Financials
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park,... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
12/08 GERON : to Host Analyst and Investor Meeting and Webcast on December 19, 2017
12/08 GERON CORPORATION : Today’s Research Reports on Trending Tickers: Geron Corporat..
12/06 Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
11/22 GERON CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fi..
11/22 GERON : Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Tria..
11/20 Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Tri..
11/10 GERON : Announces November Investor Conference Presentation Webcasts
11/07 Geron Announces November Investor Conference Presentation Webcasts
11/07 GERON : Announces Presentations at American Society of Hematology Annual Meeting
11/07 GERON CORPORATION : Reports Third Quarter 2017 Financial Results
More news
Sector news : Bio Therapeutic Drugs
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/08 YOUR DAILY PHARMA SCOOP : Geron Update, Acorda Resubmits NDA, Sage Rallies
12/06 GERON :  It's Breakout Time
12/04 Geron - Survival Mode
11/29 Geron (GERN) Presents At PiperJaffray 29th Annual Healthcare Conference - Sli..
11/20 YOUR DAILY PHARMA SCOOP : Geron's Fate, Celldex Commences Mid-Stage Study, Novar..
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 85%
EPS Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Ho Young Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Independent Director
Robert Jay Spiegel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION-8.70%323
GILEAD SCIENCES2.35%96 926
REGENERON PHARMACEUTICALS1.43%40 911
VERTEX PHARMACEUTICALS87.81%36 319
GENMAB1.62%11 562
EXELIXIS, INC.79.28%8 021